[go: up one dir, main page]

US20130066327A1 - Hydraulic cement compositions with low ph methods, articles and kits - Google Patents

Hydraulic cement compositions with low ph methods, articles and kits Download PDF

Info

Publication number
US20130066327A1
US20130066327A1 US13/229,534 US201113229534A US2013066327A1 US 20130066327 A1 US20130066327 A1 US 20130066327A1 US 201113229534 A US201113229534 A US 201113229534A US 2013066327 A1 US2013066327 A1 US 2013066327A1
Authority
US
United States
Prior art keywords
hydraulic cement
aqueous
cement composition
monocalcium phosphate
cement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/229,534
Inventor
Håkan Engqvist
Jonas Áberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OSS-Q AB
Original Assignee
OSS-Q AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OSS-Q AB filed Critical OSS-Q AB
Priority to US13/229,534 priority Critical patent/US20130066327A1/en
Assigned to OSS-Q AB reassignment OSS-Q AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ABERG, JONAS, ENGQVIST, HAKAN
Priority to PCT/IB2012/054701 priority patent/WO2013035083A2/en
Priority to US14/343,105 priority patent/US9676665B2/en
Priority to GB1405031.4A priority patent/GB2513477A/en
Publication of US20130066327A1 publication Critical patent/US20130066327A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B12/00—Cements not provided for in groups C04B7/00 - C04B11/00
    • C04B12/02—Phosphate cements
    • C04B12/025—Phosphates of ammonium or of the alkali or alkaline earth metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/56—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
    • A61B17/58—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor for osteosynthesis, e.g. bone plates, screws or setting implements
    • A61B17/88—Osteosynthesis instruments; Methods or means for implanting or extracting internal or external fixation devices
    • A61B17/8802—Equipment for handling bone cement or other fluid fillers
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B28/00—Compositions of mortars, concrete or artificial stone, containing inorganic binders or the reaction product of an inorganic and an organic binder, e.g. polycarboxylate cements
    • C04B28/02—Compositions of mortars, concrete or artificial stone, containing inorganic binders or the reaction product of an inorganic and an organic binder, e.g. polycarboxylate cements containing hydraulic cements other than calcium sulfates
    • C04B28/06—Aluminous cements
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B28/00—Compositions of mortars, concrete or artificial stone, containing inorganic binders or the reaction product of an inorganic and an organic binder, e.g. polycarboxylate cements
    • C04B28/34—Compositions of mortars, concrete or artificial stone, containing inorganic binders or the reaction product of an inorganic and an organic binder, e.g. polycarboxylate cements containing cold phosphate binders
    • C04B28/344—Compositions of mortars, concrete or artificial stone, containing inorganic binders or the reaction product of an inorganic and an organic binder, e.g. polycarboxylate cements containing cold phosphate binders the phosphate binder being present in the starting composition solely as one or more phosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/56—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B2111/00—Mortars, concrete or artificial stone or mixtures to prepare them, characterised by specific function, property or use
    • C04B2111/00474—Uses not provided for elsewhere in C04B2111/00
    • C04B2111/00836—Uses not provided for elsewhere in C04B2111/00 for medical or dental applications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
    • Y10T428/131—Glass, ceramic, or sintered, fused, fired, or calcined metal oxide or metal carbide containing [e.g., porcelain, brick, cement, etc.]

Definitions

  • the present invention is directed to hydraulic cements, and, more particularly, to non-aqueous hydraulic cement compositions or partly aqueous compositions.
  • the hydraulic cement compositions may be formed into hardened cements by contact with a hydration liquid or vapor.
  • the hydraulic cements are suitable for use as biomaterials for in vivo delivery, for example for bone and tooth-root restoration.
  • the invention is also directed to hardened cements formed from such hydraulic cement compositions and to methods of producing hardened cements.
  • the invention is further directed to kits and articles of manufacture including, inter alia, such hydraulic cement compositions.
  • CPC Self-hardening calcium phosphate cements
  • the ability of the surgeon to properly mix the cement powder and hydrating liquid and then place the cement paste in a defect within the prescribed time is a crucial factor in achieving optimum results.
  • the dry cement powder material needs to be mixed with an aqueous solution in the surgical setting, i.e., the operating room, transferred to an applicator, typically a syringe, and delivered to the desired location within the setting time.
  • Conventional cements generally have a setting time of about 15-30 minutes.
  • the methods used for mixing and transfer of cement for injection in the operating room are technically difficult and pose a risk for non-optimal material performance, e.g., early setting renders materials difficult to inject or causes phase separation, so-called filter pressing.
  • the material is typically mixed with a hydrating liquid in bulk to form a paste and the paste is then transferred to smaller syringes for delivery.
  • material is often wasted due to an early setting reaction, i.e., the hydrated material sets to a hardened cement prior to delivery to the desired location, or because more material than is needed is mixed.
  • a solution to these problems that includes the possibility to deliver material in smaller quantities in a more controlled manner is thus desired.
  • a powder composition for hydroxyapatite is premixed with an organic acid and glycerol to form a paste, which paste may subsequently be injected into a defect.
  • the injected material hardens through the diffusion of body liquids into the biomaterial.
  • the organic acid is added to increase resistance to washout and the end product after setting is apatite, which is known to have a long resorption time in vivo as described above.
  • compositions of ⁇ -tricalcium phosphate ( ⁇ -TCP) and hydrated acid calcium phosphate in glycerin or polyethylene glycol have previously been described in CN 1919357.
  • the invention is directed to a non-aqueous, hydraulic cement composition, which comprises a non-aqueous mixture of (a) ⁇ -tricalcium phosphate powder, (b) mono calcium phosphate anhydrous (MCPA) or monocalcium phosphate monohydrate (MCPM), or a combination thereof, and (c) non-aqueous water-miscible liquid.
  • a non-aqueous, hydraulic cement composition which comprises a non-aqueous mixture of (a) ⁇ -tricalcium phosphate powder, (b) mono calcium phosphate anhydrous (MCPA) or monocalcium phosphate monohydrate (MCPM), or a combination thereof, and (c) non-aqueous water-miscible liquid.
  • the MCPA and MCPM powders that in a saturated aqueous solution of the powders have a pH below 3 are used in order to obtain proper hardening.
  • the invention is directed to non-aqueous, hydraulic cement composition which comprises a non-aqueous mixture of (a) ⁇ -tricalcium phosphate powder (b) mono calcium phosphate anhydrous (MCPA) or monocalcium phosphate monohydrate (MCPM) or a combination thereof, (c) non-aqueous water-miscible liquid and d) porous ⁇ -tricalcium phosphate ( ⁇ -TCP) granules.
  • MCPA mono calcium phosphate anhydrous
  • MCPM monocalcium phosphate monohydrate
  • ⁇ -TCP porous ⁇ -tricalcium phosphate
  • water can be added to the composition.
  • 1-50 vol % water, more specifically 3-30 vol % water, or more specifically, 15-30% water, based on the volume of water and non-aqueous water miscible liquid, may be employed.
  • water, if employed, is added shortly prior to use.
  • the invention is also directed to methods of producing a hardened cement with such compositions, hardened cements produced from such compositions, kits including such compositions, and articles of manufacture including such compositions.
  • the hydraulic cement compositions according to the invention are advantageous in that they avoid many of the preparation difficulties of conventional hydraulic cement compositions, particularly when used as biomaterials, and may be easily and efficiently delivered to a desired location, without excessive material waste. Additionally, the hydraulic cement compositions according to the invention may be optimized for improved shelf life.
  • the non-aqueous, hydraulic cement compositions of the present invention are suitable, in one embodiment, for use in biomedical applications.
  • the present description refers to use of the compositions for in vivo applications, for example in bone and tooth repair. It will be appreciated that the present compositions are suitable for other in vivo applications as well as for non-biomaterial applications.
  • the compositions of the invention contain non-hydrated powder and will hydrate upon contact with a hydrating liquid or vapor, typically water, body fluids or other aqueous solution.
  • the non-aqueous, hydraulic cement composition comprises a non-aqueous mixture of (a) ⁇ -tricalcium phosphate powder, (b) mono calcium phosphate anhydrous (MCPA) or monocalcium phosphate monohydrate (MCPM) or a combination thereof, and (c) non-aqueous water-miscible liquid.
  • the cement will form Brushite (CaHPO 4 -2H 2 O) in temperature ranges of about 0-20° C. and Monetite (CaHPO 4 ) in temperature ranges of about 35-100° C. In the range between 20 and 35° C. a mixture of the two phases will form.
  • the MCPA and MCPM should exhibit a pH of below 3, and in further embodiments a pH of at least 2 in a saturated aqueous solution. In a more specific embodiment, the MCPA and MCPM should exhibit a pH of 2.5-2.8. Measurement of pH can typically be measured using a saturated aqueous solution of the powders (including glycerol), about 0.1 g/mL. The pH of these solutions can then be measured using a standard pH meter. The indicated pH allows a faster setting and more complete chemical reaction during hydration of the cement. Below pH 2, MCPA and MCPM are less soluble in water; however, a lower pH will render cements with faster setting times and are therefore preferable.
  • the monocalcium phosphate consists essentially of MCPA, whereby significant amounts of MCPM, i.e., greater than about 25%, or greater than about 10%, or greater than about 5%, based on the weight of the monocalcium phosphate, are excluded.
  • the monocalcium phosphate consists of MCPA.
  • the MCPA does not contain any crystal water as is the case with mono calcium phosphate monohydrate. This makes the inventive compositions more stable during storage, especially in temperatures below 20° C. (where brushite is formed), since any additional water in the cement formulation will be bound to the formed brushite (CaHPO 4 -2H 2 O).
  • aqueous cement compositions mixed with water benefit from smaller particle sizes in the powder composition since this gives faster setting time and stronger cements.
  • premixed cements are affected differently. When too small of particles sizes are used (i.e., mean grain size about 1 micrometer or less), the premixed cements are difficult to inject.
  • the setting time is not affected to the same extent since in addition to the non-aqueous liquid dissolution rate, the diffusion rate of water into the cement also controls the setting time. Therefore, smaller particles do not necessarily give faster setting times compared to cements with larger particles. Larger particles make the cement easier to inject than finer particle size powders.
  • the porosity is important to be able to control since the porosity affects bone ingrowth and the resorption time in vivo, Ginebra et al, “In vivo evaluation of an injectable Macroporous Calcium Phosphate Cement” Journal of Materials Science - Materials in Medicine, 18(2):353-361 (2007).
  • MCP particle size By controlling the MCP particle size it is possible to control the porosity in the cement. In previous cement formulations, additional additives were added in order to obtain the desired porosity.
  • At least 75%, at least 80%, at least 85%, or at least 90% of the MCP particles, or, more specifically, the MCPA particles are of a size about 200-600 ⁇ m, more specifically about 400-600 ⁇ m.
  • the powder to liquid ratio (P/L) is (weight/volume) about 2.5-5.5, more specifically about 3.5-5, to obtain a porous cement upon hardening, allowing for faster bone ingrowth.
  • the MCP, or specifically, MCPA, particles size is about 0.01-400 ⁇ m, more specifically about 0.01-200 ⁇ m, and most specifically, about 0.01-100 ⁇ m, but larger than about 1 ⁇ m, and the P/L is about 2-5, more specifically about 3-4.5, for a cement with higher mechanical strength.
  • the particle size range is wide, about 0.1-600 ⁇ m, and the P/L is about 2.5 and 5.5, more specifically about 3.5 and 5, for a cement with some larger pores allowing fast diffusion and that is mechanically strong.
  • the non-aqueous, hydraulic cement composition comprises a non-aqueous mixture of (a) ⁇ -tricalcium phosphate powder, (b) mono calcium phosphate anhydrous (MCPA) or monocalcium phosphate monohydrate (MCPM) or a combination thereof, preferably MCPA, (c) non-aqueous water-miscible liquid, and d) porous ⁇ -tricalcium phosphate ( ⁇ -TCP) granules.
  • the porous ⁇ -TCP granules modify the resorption rate and bone remodelling of the hardened cement which is formed upon hydration and setting.
  • the granules generally comprise agglomerated powders and the porosity of the granules comprises pores formed between individual powder grains in the agglomerates.
  • the granule size is from about 10 to about 3000 micrometers.
  • the granule size is from about 10 to about 1000 micrometers and may be selected to optimize mechanical and/or biological properties of the resulting hardened cement.
  • the granule porosity is at most 80 vol % and the pore size is at most 500 micrometers.
  • the weight ratio of porous ⁇ -TCP granules to additional powder in the non-hydrated powder composition is in a range about 1:3 to about 3:1, or, more specifically, in a range of about 2:1 to about 1:2.
  • any suitable, non-aqueous water-miscible liquid may be employed to form the premixed paste (i.e. the paste that is subsequently injected in vivo).
  • exemplary liquids include, but are not limited to, glycerol, propylene glycol, poly(propylene glycol), poly(ethylene glycol) and combinations thereof, and related liquid compounds and derivatives, i.e., substances derived from non-aqueous water miscible substances, substitutes, i.e., substances where part of the chemical structure has been substituted with another chemical structure, and the like.
  • Certain alcohols may also be suitable as mixing liquid.
  • the liquid is glycerol.
  • the powder to non-aqueous water-miscible liquid weight to volume ratio may suitably be in a range of from about 0.5 to about 10, more specifically from about 1 to about 7, and more specifically from about 2.5 to about 7, or from about 2.5 to about 5, for better handling and mechanical strength. These ratios are suitable even if two or more liquids are used in combination.
  • the hydraulic cement compositions of the invention may also include agents that facilitate a fast diffusion of water formed in situ into the paste which is formed by the powder composition and the non-aqueous liquid.
  • the agent comprises a surfactant, more specifically a non-ionic surfactant, an example of which includes, but is not limited to, a polysorbate.
  • the amount of surfactant may vary from about 0.01 to about 5 weight % of the powder composition, or, more specifically, from about 0.1 to about 1 weight %. See, for example, Shimada et al, “Properties of Injectable Apatite-Forming Premixed Cements”, Journal of Research of the National Institute of Standards and Technology, 115(4):240 (July-August 2010).
  • the hydraulic cement compositions of the invention may also include one or more porogens to provide a macroporous cement product.
  • a macroporous cement product facilitates fast resorption and tissue in-growth.
  • the porogen may include sugars and other fast-resorbing agents, and non-limiting examples include calcium sulphate, mannitol, poly(a-hydroxy ester) foams, sucrose, NaHCO 3 , NaCl and sorbitol.
  • the amount of porogen may suitably be from about 5 to about 30 weight % of the powder composition.
  • the grain size of the porogens are typically in the range of 50 to 600 ⁇ m.
  • the hydraulic cement compositions of the invention may also include one or more non-toxic gelling agents to enhance cohesiveness and washout resistance of the compositions upon delivery.
  • exemplary gelling agents include, but are not limited to, chitosan, collagen, gum, gelatin, alginate, cellulose, polyacrylic acid (PAA), polyacrylic maleic acid (PAMA), polymethacrylic acid (PMA), neutral polyacrylic and/or polymethacrylic acid and/or polyacrylmaleic acid (e.g. Na-PAA, Na-PMA, Na-PAMA), hydroxypropylmethyl cellulose (HPMC), hydroxymethyl cellulose (HMC), polyvinylpyrrolidone (PVP), and carboxymethyl cellulose (CMC), and combinations thereof.
  • the amount of gelling agent represents suitably from about 0.1 to about 7 weight % of the powder composition, more specifically from about 0.1 to about 2 weight %.
  • the hydraulic cement compositions are formed into hardened cement materials by contact with a hydrating liquid or vapor.
  • a hydrating liquid is employed.
  • the hydration liquid may be any polar liquid, such as water and other polar protic solvents (e.g. alcohol).
  • the hydrating liquid is suitably water or an aqueous solution.
  • the hydrating liquid can optionally have a pH within the range of 1-9.
  • the powder compositions as described in the present invention are premixed with a liquid containing a combination of non-aqueous liquid and water.
  • the water concentration is suitably below 50% (vol/vol), more preferably about 10-40% or about 15-30% (vol/vol), based on both the non-aqueous liquid and water.
  • the hydraulic cement compositions in the form of a premixed paste may be delivered, for example, to an implant site when used as a biomaterial, using a syringe or spatula.
  • the hydraulic cement compositions may be shaped in vivo, and subsequently be hydrated or be allowed to hydrate in vivo.
  • a water-containing liquid can be added to the premixed paste before delivery, for example before applying the material in vivo using a spatula.
  • the hydraulic cement compositions in the form of a premixed paste can also be packaged in a vacuum package to reduce the amount of air voids in the paste and thus increase the final strength of the hardened material. Air voids reduce the strength of the set material and reduction of air voids is therefore important.
  • the hydraulic cement compositions may be conveniently mixed and packaged under vacuum conditions. Preferably the hydraulic cement compositions are vacuum-mixed (e.g. in a Ross Vacuum Mixer Homogenizer).
  • the hydraulic cement compositions may be provided as a component of a kit or article of manufacture, for example in combination with a separately contained quantity of hydrating liquid or in a double barrel syringe with the reactive components separated in two barrels.
  • a kit comprises several prefilled syringes of the same or of various sizes.
  • Another non-limiting example is a kit with several 2 ml prefilled syringes.
  • Another non-limiting example is a kit with several 1 ml prefilled syringes.
  • another embodiment of the invention comprises an article of manufacture comprising a hydraulic cement composition in a dispensing container, more specifically a syringe.
  • the cement compositions is provided in a jar, then the cement is preferably applied using a special device, for example, a spatula or a spoon.
  • the described hydraulic cement compositions are suitably employed as injectable in situ-setting biomaterials or as putties.
  • the compositions can be used as any implant, more specifically as a bone implant, more specifically as dental or orthopedic implant.
  • the hydraulic cement compositions are suitable used as material in cranio maxillofacial defects (CMF), bone void filler, trauma, spinal, endodontic, intervertebral disc replacement and percutaneous vertebroplasty (vertebral compression fracture) applications.
  • CMF cranio maxillofacial defects
  • bone void filler trauma, spinal, endodontic, intervertebral disc replacement and percutaneous vertebroplasty (vertebral compression fracture) applications.
  • This example shows the effect of the pH of monocalcium phosphate has on the setting properties of the cement formulation.
  • Monocalcium phosphate monohydrate and anhydrous from 5 different suppliers were evaluated. When the anhydrous form could not be obtained from the supplier, the MCPM was heated to 120° in order to form MCPA. The particle size of the tested MCPA and MCPM powders was in the range of 10-400 ⁇ m. Saturated aqueous solutions of the powders (including glycerol) were prepared (0.1 g/mL). The pH of these solutions was measured using a standard pH meter. The different MCPA and MCPM powders were then used in cement formulations prepared with a powder to liquid ratio of 3.5 g/mL. The cements were evaluated regarding setting time.
  • This example shows that use of MCPA instead of MCPM increases the shelf life of the cement formulation.
  • the shelf life in room temperature of the cement using MCPA was significantly longer than when using MCPM.
  • Cement 1 consisted of monocalcium phosphate hydrate (Alpha Aesar, containing both MCPM and MCPA) and ⁇ -tri calcium phosphate ( ⁇ -TCP, Sigma) in a molar ratio of 1:1.
  • Anhydrous glycerol was used as mixing liquid.
  • Cement 2 consisted of monocalcium phosphate anhydrous (MCPA) and ⁇ -tri calcium phosphate ( ⁇ -TCP) in a molar ratio of 1:1.
  • Anhydrous glycerol was used as mixing liquid.
  • a powder to liquid ratio (P/L) of 4 (g/ml) was used for both cements.
  • the MCPA was produced by heating the monocalcium phosphate hydrate powder to 110° C. for 24 h.
  • a vacuum mixer was used to mix the cements.
  • PBS phosphate buffered saline solution
  • the paste was injected into cylindrical moulds and immersed in 50 ml PBS at 37° C. in a sealed beaker. Sample dimensions were diameter 6 mm and height 12 mm. After 24 h, the samples were removed from the moulds and carefully polished to obtain the correct height and parallel surfaces. The maximum compressive stress until failure was measured.
  • This example shows a number of formulations using MCPA with different particle sizes and powder to liquid ratios. The results show that a larger grain size of the MCPA provides means to control the setting time, injection force and strength of the hardened material.
  • the cement consisted of monocalcium phosphate anhydrous (MCPA) and ⁇ -tri calcium phosphate ( ⁇ -TCP), in a molar ratio of 1:1. Glycerol (anhydrous) was used as mixing liquid.
  • the MCPA was sieved in order to obtain the following particle sizes: ⁇ 100 ⁇ m, 100-200 ⁇ m, 200-400 ⁇ m, and 400-600 ⁇ m.
  • MCPA was also used as received, containing all the mentioned particle sizes, hereby referred to as ALL.
  • a vacuum mixer was used to mix the cements. All evaluated cement mixtures are listed in the Table 3:
  • the injectability was evaluated by measuring the force needed to inject 2 ml of cement paste from a disposable syringe; barrel diameter 8.55 mm, outlet diameter 1.90 mm.
  • the force applied to the syringe during the injection was measured and mean injection force from 10 to 30 mm displacement was calculated, this force is referred to as the injection force.
  • PBS phosphate buffered saline solution
  • the paste was injected into cylindrical moulds and immersed in 50 ml PBS at 37° C. in a sealed beaker. Sample dimensions were diameter 6 mm and height 12 mm. After 24 h, the samples were removed from the moulds and carefully polished to obtain the correct height and parallel surfaces. The maximum compressive stress until failure was measured.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ceramic Engineering (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials For Medical Uses (AREA)
  • Nanotechnology (AREA)

Abstract

A non-aqueous hydraulic cement composition comprises a non-aqueous mixture of (a) β-tricalcium phosphate powder, (b) monocalcium phosphate comprising monocalcium phosphate anhydrous (MCPA), monocalcium phosphate monohydrate (MCPM), or a combination thereof, and (c) non-aqueous water-miscible liquid, wherein a 0.1 g/ml saturated aqueous solution of the monocalcium phosphate has a pH less than 3.0. Methods of producing a hardened cement, hardened cements, kits, and articles of manufacture employ such compositions.

Description

    FIELD OF THE INVENTION
  • The present invention is directed to hydraulic cements, and, more particularly, to non-aqueous hydraulic cement compositions or partly aqueous compositions. The hydraulic cement compositions may be formed into hardened cements by contact with a hydration liquid or vapor. In a specific embodiment, the hydraulic cements are suitable for use as biomaterials for in vivo delivery, for example for bone and tooth-root restoration. The invention is also directed to hardened cements formed from such hydraulic cement compositions and to methods of producing hardened cements. The invention is further directed to kits and articles of manufacture including, inter alia, such hydraulic cement compositions.
    • BACKGROUND OF THE INVENTION
  • Self-hardening calcium phosphate cements (CPC) have been used for bone and tooth restoration and for local drug delivery applications. See, for example, Larsson et al, “Use of injectable calcium phosphate cement for fracture fixation: A review,” Clinical Orthopedics and Related Research, 395:23-32 (2002) and Oda et al, “Clinical use of a newly developed calcium phosphate cement (XSB-671D),” Journal of Orthopedic Science, 11(2):167-174 (2006). The cements in powder form are typically mixed with an aqueous solution immediately before application. In the clinical situation, the ability of the surgeon to properly mix the cement powder and hydrating liquid and then place the cement paste in a defect within the prescribed time is a crucial factor in achieving optimum results. Specifically, the dry cement powder material needs to be mixed with an aqueous solution in the surgical setting, i.e., the operating room, transferred to an applicator, typically a syringe, and delivered to the desired location within the setting time. Conventional cements generally have a setting time of about 15-30 minutes. However, the methods used for mixing and transfer of cement for injection in the operating room are technically difficult and pose a risk for non-optimal material performance, e.g., early setting renders materials difficult to inject or causes phase separation, so-called filter pressing. Further, for technical reasons and time constraints, the material is typically mixed with a hydrating liquid in bulk to form a paste and the paste is then transferred to smaller syringes for delivery. In practice, material is often wasted due to an early setting reaction, i.e., the hydrated material sets to a hardened cement prior to delivery to the desired location, or because more material than is needed is mixed. A solution to these problems that includes the possibility to deliver material in smaller quantities in a more controlled manner is thus desired.
  • The problem of obtaining a proper mix of the powder material and hydrating liquid for optimum clinical results in apatite cements has been addressed in US 2006/0263443, US 2007/0092856, Carey et al, “Premixed rapid-setting calcium phosphate composites for bone repair,” Biomaterials, 26(24):5002-5014 (2005), Takagi et al, “Premixed calcium-phosphate cement pastes,” Journal of Biomedical Materials Research Part B-Applied Biomaterials, 67B(2): 689-696 (2003), Xu et al, “Premixed macroporous calcium phosphate cement scaffold,” Journal of Materials Science-Materials in Medicine, 18(7):1345-1353 (2007), and Xu et al, “Premixed calcium phosphate cements: Synthesis, physical properties, and cell cytotoxicity,” Dental Materials, 23(4):433-441 (2007), wherein premixed pastes are described. In US 2006/0263443, for example, a powder composition for hydroxyapatite is premixed with an organic acid and glycerol to form a paste, which paste may subsequently be injected into a defect. The injected material hardens through the diffusion of body liquids into the biomaterial. The organic acid is added to increase resistance to washout and the end product after setting is apatite, which is known to have a long resorption time in vivo as described above. Also, compositions of β-tricalcium phosphate (β-TCP) and hydrated acid calcium phosphate in glycerin or polyethylene glycol have previously been described in CN 1919357. Han et al, “β-TCP/MCPM-based premixed calcium phosphate cements,” Acta Biomaterialia, doi:10.1016/j.actbio.2009.04.024 (2009) and Aberg et al, “Premixed acidic calcium phosphate cement: characterization of strength and microstructure, Journal of Biomedical Materials Research, 2010, May; 93(2):436-41. However, it is difficult to obtain sufficient shelf life using the described formulations in the prior art, as also noted by Shimada et al, Journal of Research of the National Institute of Standards and Technology “Properties of Injectable Apatite-Forming Premixed Cements,” 115(4): 240 (July-August 2010). Shelf life is also a problem for reactive Brushite forming cements. Tests have been performed using monocalcium phosphate anhydrous (MCPA), where difficulties to achieve a rapid setting time resulted when changing from MCPM (monocalcium phosphate monohydrate) to MCPA.
  • Thus, there is a continuing need to be able to efficiently prepare, store and safely deliver hydraulic cements, particularly for biomedical applications, i.e., hydraulic cements that overcome the above noted and/or other difficulties of conventional hydraulic cement materials, while optionally optimizing performance properties.
    • SUMMARY OF THE INVENTION
  • Accordingly, it is an object of the present invention to provide hydraulic cements, and hardened cements, methods, kits and articles of manufacture based on the hydraulic cements, with an optimized handling and biological response for clinical use.
  • In one embodiment, the invention is directed to a non-aqueous, hydraulic cement composition, which comprises a non-aqueous mixture of (a) β-tricalcium phosphate powder, (b) mono calcium phosphate anhydrous (MCPA) or monocalcium phosphate monohydrate (MCPM), or a combination thereof, and (c) non-aqueous water-miscible liquid.
  • In the specific embodiment the MCPA and MCPM powders that in a saturated aqueous solution of the powders have a pH below 3 are used in order to obtain proper hardening.
  • In another embodiment, the invention is directed to non-aqueous, hydraulic cement composition which comprises a non-aqueous mixture of (a) β-tricalcium phosphate powder (b) mono calcium phosphate anhydrous (MCPA) or monocalcium phosphate monohydrate (MCPM) or a combination thereof, (c) non-aqueous water-miscible liquid and d) porous β-tricalcium phosphate (β-TCP) granules. In most bone applications, it is preferred to have a cement composition that resembles natural bone the most. As such calcium phosphate cement is the preferred cement over other compositions.
  • To achieve a faster setting time and also allow for hardening of large amounts of injected material, water can be added to the composition. In one embodiment, 1-50 vol % water, more specifically 3-30 vol % water, or more specifically, 15-30% water, based on the volume of water and non-aqueous water miscible liquid, may be employed. Typically, water, if employed, is added shortly prior to use.
  • The invention is also directed to methods of producing a hardened cement with such compositions, hardened cements produced from such compositions, kits including such compositions, and articles of manufacture including such compositions.
  • The hydraulic cement compositions according to the invention are advantageous in that they avoid many of the preparation difficulties of conventional hydraulic cement compositions, particularly when used as biomaterials, and may be easily and efficiently delivered to a desired location, without excessive material waste. Additionally, the hydraulic cement compositions according to the invention may be optimized for improved shelf life. These and additional objects and advantages of the present invention will be more fully appreciated in view of the following detailed description.
    • DETAILED DESCRIPTION
  • The non-aqueous, hydraulic cement compositions of the present invention are suitable, in one embodiment, for use in biomedical applications. The present description refers to use of the compositions for in vivo applications, for example in bone and tooth repair. It will be appreciated that the present compositions are suitable for other in vivo applications as well as for non-biomaterial applications. The compositions of the invention contain non-hydrated powder and will hydrate upon contact with a hydrating liquid or vapor, typically water, body fluids or other aqueous solution.
  • In a first embodiment, the non-aqueous, hydraulic cement composition comprises a non-aqueous mixture of (a) β-tricalcium phosphate powder, (b) mono calcium phosphate anhydrous (MCPA) or monocalcium phosphate monohydrate (MCPM) or a combination thereof, and (c) non-aqueous water-miscible liquid. After hardening, the cement will form Brushite (CaHPO4-2H2O) in temperature ranges of about 0-20° C. and Monetite (CaHPO4) in temperature ranges of about 35-100° C. In the range between 20 and 35° C. a mixture of the two phases will form.
  • The MCPA and MCPM should exhibit a pH of below 3, and in further embodiments a pH of at least 2 in a saturated aqueous solution. In a more specific embodiment, the MCPA and MCPM should exhibit a pH of 2.5-2.8. Measurement of pH can typically be measured using a saturated aqueous solution of the powders (including glycerol), about 0.1 g/mL. The pH of these solutions can then be measured using a standard pH meter. The indicated pH allows a faster setting and more complete chemical reaction during hydration of the cement. Below pH 2, MCPA and MCPM are less soluble in water; however, a lower pH will render cements with faster setting times and are therefore preferable.
  • In one embodiment, the monocalcium phosphate consists essentially of MCPA, whereby significant amounts of MCPM, i.e., greater than about 25%, or greater than about 10%, or greater than about 5%, based on the weight of the monocalcium phosphate, are excluded. In another embodiment, the monocalcium phosphate consists of MCPA. The MCPA does not contain any crystal water as is the case with mono calcium phosphate monohydrate. This makes the inventive compositions more stable during storage, especially in temperatures below 20° C. (where brushite is formed), since any additional water in the cement formulation will be bound to the formed brushite (CaHPO4-2H2O).
  • Generally aqueous cement compositions mixed with water benefit from smaller particle sizes in the powder composition since this gives faster setting time and stronger cements. However, it has been discovered that premixed cements are affected differently. When too small of particles sizes are used (i.e., mean grain size about 1 micrometer or less), the premixed cements are difficult to inject. For the premixed cements, the setting time is not affected to the same extent since in addition to the non-aqueous liquid dissolution rate, the diffusion rate of water into the cement also controls the setting time. Therefore, smaller particles do not necessarily give faster setting times compared to cements with larger particles. Larger particles make the cement easier to inject than finer particle size powders. While not wishing to be bound by theory, it is believed that there is more glycerol (on average) between each powder grain, resulting in an easier shear of the cement paste and easier injection. In addition, the porosity is important to be able to control since the porosity affects bone ingrowth and the resorption time in vivo, Ginebra et al, “In vivo evaluation of an injectable Macroporous Calcium Phosphate Cement” Journal of Materials Science-Materials in Medicine, 18(2):353-361 (2007). By controlling the MCP particle size it is possible to control the porosity in the cement. In previous cement formulations, additional additives were added in order to obtain the desired porosity. Furthermore, conventional water mixed cements harden without any substantial liquid exchange in vivo since the water present in the cement is enough for the hardening to occur. For the cements in the present invention, a liquid exchange must occur between the non-hydrated liquid in the cement and hydration liquid, i.e., the surrounding body fluid (blood) in vivo use. During this liquid exchange, biological components will be transported into the cement, which are beneficial for faster bone ingrowth and resorption of the cement. This liquid exchange will benefit from larger particle sizes that allow a quicker liquid exchange during hardening through the larger pores, which are formed when the MCPM and/or MCPA dissolves and since there is more glycerol (on average) between each powder grain.
  • In specific embodiments, at least 75%, at least 80%, at least 85%, or at least 90% of the MCP particles, or, more specifically, the MCPA particles, are of a size about 200-600 μm, more specifically about 400-600 μm. In specific embodiments, the powder to liquid ratio (P/L) is (weight/volume) about 2.5-5.5, more specifically about 3.5-5, to obtain a porous cement upon hardening, allowing for faster bone ingrowth. In further embodiments, the MCP, or specifically, MCPA, particles size is about 0.01-400 μm, more specifically about 0.01-200 μm, and most specifically, about 0.01-100 μm, but larger than about 1 μm, and the P/L is about 2-5, more specifically about 3-4.5, for a cement with higher mechanical strength. In a specific embodiment, the particle size range is wide, about 0.1-600 μm, and the P/L is about 2.5 and 5.5, more specifically about 3.5 and 5, for a cement with some larger pores allowing fast diffusion and that is mechanically strong.
  • In a further embodiment, the non-aqueous, hydraulic cement composition comprises a non-aqueous mixture of (a) β-tricalcium phosphate powder, (b) mono calcium phosphate anhydrous (MCPA) or monocalcium phosphate monohydrate (MCPM) or a combination thereof, preferably MCPA, (c) non-aqueous water-miscible liquid, and d) porous β-tricalcium phosphate (β-TCP) granules. The porous β-TCP granules modify the resorption rate and bone remodelling of the hardened cement which is formed upon hydration and setting. The granules generally comprise agglomerated powders and the porosity of the granules comprises pores formed between individual powder grains in the agglomerates. In a specific embodiment, the granule size is from about 10 to about 3000 micrometers. In a further embodiment, the granule size is from about 10 to about 1000 micrometers and may be selected to optimize mechanical and/or biological properties of the resulting hardened cement. In a specific embodiment, the granule porosity is at most 80 vol % and the pore size is at most 500 micrometers.
  • In a specific embodiment, the weight ratio of porous β-TCP granules to additional powder in the non-hydrated powder composition is in a range about 1:3 to about 3:1, or, more specifically, in a range of about 2:1 to about 1:2.
  • In the first and second embodiments of the invention as described above, any suitable, non-aqueous water-miscible liquid may be employed to form the premixed paste (i.e. the paste that is subsequently injected in vivo). Exemplary liquids include, but are not limited to, glycerol, propylene glycol, poly(propylene glycol), poly(ethylene glycol) and combinations thereof, and related liquid compounds and derivatives, i.e., substances derived from non-aqueous water miscible substances, substitutes, i.e., substances where part of the chemical structure has been substituted with another chemical structure, and the like. Certain alcohols may also be suitable as mixing liquid. In a specific embodiment, the liquid is glycerol.
  • The powder to non-aqueous water-miscible liquid weight to volume ratio (P/L) may suitably be in a range of from about 0.5 to about 10, more specifically from about 1 to about 7, and more specifically from about 2.5 to about 7, or from about 2.5 to about 5, for better handling and mechanical strength. These ratios are suitable even if two or more liquids are used in combination.
  • The hydraulic cement compositions of the invention may also include agents that facilitate a fast diffusion of water formed in situ into the paste which is formed by the powder composition and the non-aqueous liquid. In one embodiment, the agent comprises a surfactant, more specifically a non-ionic surfactant, an example of which includes, but is not limited to, a polysorbate. The amount of surfactant may vary from about 0.01 to about 5 weight % of the powder composition, or, more specifically, from about 0.1 to about 1 weight %. See, for example, Shimada et al, “Properties of Injectable Apatite-Forming Premixed Cements”, Journal of Research of the National Institute of Standards and Technology, 115(4):240 (July-August 2010).
  • The hydraulic cement compositions of the invention may also include one or more porogens to provide a macroporous cement product. A macroporous cement product facilitates fast resorption and tissue in-growth. The porogen may include sugars and other fast-resorbing agents, and non-limiting examples include calcium sulphate, mannitol, poly(a-hydroxy ester) foams, sucrose, NaHCO3, NaCl and sorbitol. The amount of porogen may suitably be from about 5 to about 30 weight % of the powder composition. The grain size of the porogens are typically in the range of 50 to 600 μm.
  • The hydraulic cement compositions of the invention may also include one or more non-toxic gelling agents to enhance cohesiveness and washout resistance of the compositions upon delivery. Exemplary gelling agents include, but are not limited to, chitosan, collagen, gum, gelatin, alginate, cellulose, polyacrylic acid (PAA), polyacrylic maleic acid (PAMA), polymethacrylic acid (PMA), neutral polyacrylic and/or polymethacrylic acid and/or polyacrylmaleic acid (e.g. Na-PAA, Na-PMA, Na-PAMA), hydroxypropylmethyl cellulose (HPMC), hydroxymethyl cellulose (HMC), polyvinylpyrrolidone (PVP), and carboxymethyl cellulose (CMC), and combinations thereof. The amount of gelling agent represents suitably from about 0.1 to about 7 weight % of the powder composition, more specifically from about 0.1 to about 2 weight %.
  • The hydraulic cement compositions are formed into hardened cement materials by contact with a hydrating liquid or vapor. In a specific embodiment, a hydrating liquid is employed. The hydration liquid may be any polar liquid, such as water and other polar protic solvents (e.g. alcohol). The hydrating liquid is suitably water or an aqueous solution. The hydrating liquid can optionally have a pH within the range of 1-9. According to one embodiment; the powder compositions as described in the present invention are premixed with a liquid containing a combination of non-aqueous liquid and water. When used, the water concentration is suitably below 50% (vol/vol), more preferably about 10-40% or about 15-30% (vol/vol), based on both the non-aqueous liquid and water.
  • The hydraulic cement compositions in the form of a premixed paste may be delivered, for example, to an implant site when used as a biomaterial, using a syringe or spatula. The hydraulic cement compositions may be shaped in vivo, and subsequently be hydrated or be allowed to hydrate in vivo. Optionally, a water-containing liquid can be added to the premixed paste before delivery, for example before applying the material in vivo using a spatula.
  • The hydraulic cement compositions in the form of a premixed paste can also be packaged in a vacuum package to reduce the amount of air voids in the paste and thus increase the final strength of the hardened material. Air voids reduce the strength of the set material and reduction of air voids is therefore important. The hydraulic cement compositions may be conveniently mixed and packaged under vacuum conditions. Preferably the hydraulic cement compositions are vacuum-mixed (e.g. in a Ross Vacuum Mixer Homogenizer).
  • In another embodiment of the invention, the hydraulic cement compositions may be provided as a component of a kit or article of manufacture, for example in combination with a separately contained quantity of hydrating liquid or in a double barrel syringe with the reactive components separated in two barrels. In a specific embodiment, a kit comprises several prefilled syringes of the same or of various sizes. Another non-limiting example is a kit with several 2 ml prefilled syringes. Another non-limiting example is a kit with several 1 ml prefilled syringes. Thus, another embodiment of the invention comprises an article of manufacture comprising a hydraulic cement composition in a dispensing container, more specifically a syringe. In another non-limiting example, the cement compositions is provided in a jar, then the cement is preferably applied using a special device, for example, a spatula or a spoon.
  • The described hydraulic cement compositions are suitably employed as injectable in situ-setting biomaterials or as putties. The compositions can be used as any implant, more specifically as a bone implant, more specifically as dental or orthopedic implant. In a specific embodiment, the hydraulic cement compositions are suitable used as material in cranio maxillofacial defects (CMF), bone void filler, trauma, spinal, endodontic, intervertebral disc replacement and percutaneous vertebroplasty (vertebral compression fracture) applications.
  • Various embodiments of the invention are illustrated in the following Examples.
    • Example 1
  • This example shows the effect of the pH of monocalcium phosphate has on the setting properties of the cement formulation.
  • Monocalcium phosphate monohydrate and anhydrous from 5 different suppliers were evaluated. When the anhydrous form could not be obtained from the supplier, the MCPM was heated to 120° in order to form MCPA. The particle size of the tested MCPA and MCPM powders was in the range of 10-400 μm. Saturated aqueous solutions of the powders (including glycerol) were prepared (0.1 g/mL). The pH of these solutions was measured using a standard pH meter. The different MCPA and MCPM powders were then used in cement formulations prepared with a powder to liquid ratio of 3.5 g/mL. The cements were evaluated regarding setting time.
    • Setting Time (ST)
  • To evaluate setting time of the cements, they were injected in five cylindrical moulds, diameter 6 mm, height 3 mm. At t=0, the filled moulds were immersed in 37° C. phosphate buffered saline solution (PBS, pH 7.4, Sigma), to simulate in vivo conditions. The cement was considered to have set when the sample could support the 453.5 g Gillmore needle with a tip diameter of 1.06 mm without breaking.
  • The results are set forth in Table 1:
  • TABLE 1
    pH and setting time using various MCPA and MCPM
    Supplier pH Setting time
    Scharlau: MCPM 2.8 ~40 min
    Scharlau: MCPA 2.8 ~40 min
    Innophos MCPM 3.5 No setting
    Innophos MCPA 3.5 No setting
    HiMed, MCPM 3.5 No setting
    HiMed, MCPA 3.5 No setting
    Chempur, MCPM 2.7 ~40 min
    Chempur, MCPA 2.8 ~40 min
    Strem, MCPM 2.5 ~40 min
    Strem, MCPA 2.6 ~40 min
  • The results show the importance of pH of the MCPM or MCPA for the setting of the cement.
    • Example 2
  • This example shows that use of MCPA instead of MCPM increases the shelf life of the cement formulation. The shelf life in room temperature of the cement using MCPA was significantly longer than when using MCPM.
    • Cement Preparation
  • Two cement formulations were evaluated. Cement 1 consisted of monocalcium phosphate hydrate (Alpha Aesar, containing both MCPM and MCPA) and β-tri calcium phosphate (β-TCP, Sigma) in a molar ratio of 1:1. Anhydrous glycerol was used as mixing liquid. Cement 2 consisted of monocalcium phosphate anhydrous (MCPA) and β-tri calcium phosphate (β-TCP) in a molar ratio of 1:1. Anhydrous glycerol was used as mixing liquid. A powder to liquid ratio (P/L) of 4 (g/ml) was used for both cements. The MCPA was produced by heating the monocalcium phosphate hydrate powder to 110° C. for 24 h. A vacuum mixer was used to mix the cements.
    • Setting Time (ST)
  • To evaluate setting time, the cement was injected in four cylindrical moulds, diameter 6 mm, height 3 mm. At t=0, the filled moulds were immersed in 37° C. phosphate buffered saline solution (PBS, pH 7.4, Sigma), to simulate in vivo conditions. The cement was considered to have set when the sample could support the 453.5 g Gillmore needle with a tip diameter of 1.06 mm without breaking.
    • Compressive Strength (CS)
  • For CS measurements, the paste was injected into cylindrical moulds and immersed in 50 ml PBS at 37° C. in a sealed beaker. Sample dimensions were diameter 6 mm and height 12 mm. After 24 h, the samples were removed from the moulds and carefully polished to obtain the correct height and parallel surfaces. The maximum compressive stress until failure was measured.
    • Shelf Life
  • 2 ml syringes were filled with cement, the syringes were then sealed and stored in a desiccator at 5 and 21° C. Cement was extruded from the syringes every 3 days until the cement had become too hard to be extruded.
  • The results are set forth in Table 2:
  • TABLE 2
    Results
    Cement 1 Cement 2
    Property (MCPM + MCPA) (MCPA)
    Setting time 30-40 min 30-40 min
    Compressive strength 8-10 MPa 8-10 MPa
    Shelf life, 21° C. 9 days 27 days
    • Example 3
  • This example shows a number of formulations using MCPA with different particle sizes and powder to liquid ratios. The results show that a larger grain size of the MCPA provides means to control the setting time, injection force and strength of the hardened material.
    • Cement Preparation
  • The cement consisted of monocalcium phosphate anhydrous (MCPA) and β-tri calcium phosphate (β-TCP), in a molar ratio of 1:1. Glycerol (anhydrous) was used as mixing liquid. The MCPA was sieved in order to obtain the following particle sizes: <100 μm, 100-200 μm, 200-400 μm, and 400-600 μm. MCPA was also used as received, containing all the mentioned particle sizes, hereby referred to as ALL. A vacuum mixer was used to mix the cements. All evaluated cement mixtures are listed in the Table 3:
  • TABLE 3
    Evaluated Cements
    Particle size (μm) P/L (g/ml)
    <100 3.9, 4.2
    100-200 4.0, 4.2
    200-400 4.2
    400-600 4.2, 4.4
    ALL 4.2
    • Injectability
  • The injectability was evaluated by measuring the force needed to inject 2 ml of cement paste from a disposable syringe; barrel diameter 8.55 mm, outlet diameter 1.90 mm. The force applied to the syringe during the injection was measured and mean injection force from 10 to 30 mm displacement was calculated, this force is referred to as the injection force.
    • Setting Time (ST)
  • To evaluate setting time, the cement was injected in four cylindrical moulds diameter 6 mm, height 3 mm. At t=0, the filled moulds were immersed in 37° C. phosphate buffered saline solution (PBS, pH 7.4, Sigma), to simulate in vivo conditions. The cement was considered to have set when the sample could support the 453.5 g Gillmore needle with a tip diameter of 1.06 mm without breaking.
    • Compressive Strength (CS)
  • For CS measurements, the paste was injected into cylindrical moulds and immersed in 50 ml PBS at 37° C. in a sealed beaker. Sample dimensions were diameter 6 mm and height 12 mm. After 24 h, the samples were removed from the moulds and carefully polished to obtain the correct height and parallel surfaces. The maximum compressive stress until failure was measured.
  • The results are set forth in Table 4:
  • TABLE 4
    Results
    Grain size P/L Injection Setting time Compressive
    (μm) (g/mL) force (N) (min) strength (MPa)
    <100 3.9 120 ± 10 30-40 10-13
    <100 4.2 240 ± 10 25-35 12-13
    100-200 4.0 100 ± 10 30-40  9-12
    100-200 4.2 180 ± 10 25-35 10-12
    200-400 4.2 100 ± 10 25-35 7-9
    400-600 4.2  90 ± 10 30-40 6-8
    400-600 4.4 180 ± 10 25-35 7-9
    ALL 4.2 110 ± 10 25-35  8-10
  • The specific examples and embodiments described herein are exemplary only in nature and are not intended to be limiting of the invention defined by the claims. Further embodiments and examples, and advantages thereof, will be apparent to one of ordinary skill in the art in view of this specification and are within the scope of the claimed invention.

Claims (20)

1. A non-aqueous hydraulic cement composition, comprising a non-aqueous mixture of (a) β-tricalcium phosphate powder, (b) monocalcium phosphate comprising monocalcium phosphate anhydrous (MCPA), monocalcium phosphate monohydrate (MCPM), or a combination thereof, and (c) non-aqueous water-miscible liquid, wherein a 0.1 g/ml saturated aqueous solution of the monocalcium phosphate has a pH less than 3.0.
2. The non-aqueous hydraulic cement composition of claim 1, wherein a 0.1 g/ml saturated aqueous solution of the monocalcium phosphate has a pH less than 3.0 and greater than 2.0.
3. The non-aqueous hydraulic cement composition of claim 1, wherein a 0.1 g/ml saturated aqueous solution of the monocalcium phosphate has a pH of about 2.5-2.8.
4. The non-aqueous hydraulic cement composition of claim 1, wherein the monocalcium phosphate comprises monocalcium phosphate anhydrous (MCPA).
5. The non-aqueous hydraulic cement composition of claim 4, wherein the monocalcium phosphate consists essentially of monocalcium phosphate anhydrous (MCPA).
6. The non-aqueous hydraulic cement composition of claim 4, wherein at least 75% of the monocalcium phosphate has a particle size in a range of about 200-600 μm.
7. The non-aqueous hydraulic cement composition of claim 6, wherein the composition has a powder (weight) to liquid (volume) ratio of about 2-5.
8. The non-aqueous hydraulic cement composition of claim 4, wherein at least 75% of the monocalcium phosphate has a particle size in a range of about 1-100 μm.
9. The non-aqueous hydraulic cement composition of claim 8, wherein the composition has a powder (weight) to liquid (volume) ratio of about 3-4.5.
10. The non-aqueous hydraulic cement composition of claim 1, further comprising porous β-tricalcium phosphate granules.
11. The non-aqueous hydraulic cement composition of claim 1, wherein the composition has a powder (weight) to liquid (volume) ratio of about 0.5-10.
12. The non-aqueous hydraulic cement composition of claim 1, further comprising one or more of a surfactant, a porogen and a gelling agent.
13. A method of preparing a hardened cement, comprising contacting the hydraulic cement composition of claim 1 with a hydrating liquid.
14. The method of claim 13, wherein the hydrating liquid comprises water.
15. A hardened cement formed according to the method of claim 13.
16. The method of claim 13, wherein the non-aqueous hydraulic cement composition is injected in vivo and the hydrating liquid comprises a body fluid.
17. An article of manufacture comprising a container filled with the non-aqueous hydraulic cement composition of claim 1.
18. The article of manufacture of claim 17, wherein the container is a syringe.
19. The article of manufacture of claim 17, wherein the container is a vacuum package.
20. A kit comprising an article of manufacture according to claim 17 and a separately-contained quantity of hydrating liquid.
US13/229,534 2011-09-09 2011-09-09 Hydraulic cement compositions with low ph methods, articles and kits Abandoned US20130066327A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US13/229,534 US20130066327A1 (en) 2011-09-09 2011-09-09 Hydraulic cement compositions with low ph methods, articles and kits
PCT/IB2012/054701 WO2013035083A2 (en) 2011-09-09 2012-09-10 Storage stable premixed hydraulic cement compositions, cements, methods, and articles
US14/343,105 US9676665B2 (en) 2011-09-09 2012-09-10 Storage stable premixed hydraulic cement compositions, cements, methods, and articles
GB1405031.4A GB2513477A (en) 2011-09-09 2012-09-10 Storage stable premixed hydraulic cement compositions, cements, methods, and articles

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/229,534 US20130066327A1 (en) 2011-09-09 2011-09-09 Hydraulic cement compositions with low ph methods, articles and kits

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US13/229,539 Continuation-In-Part US20130066324A1 (en) 2011-09-09 2011-09-09 Hydraulic cements, methods and products
US13/229,539 Continuation US20130066324A1 (en) 2011-09-09 2011-09-09 Hydraulic cements, methods and products

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/343,105 Continuation-In-Part US9676665B2 (en) 2011-09-09 2012-09-10 Storage stable premixed hydraulic cement compositions, cements, methods, and articles
US14/343,105 Continuation US9676665B2 (en) 2011-09-09 2012-09-10 Storage stable premixed hydraulic cement compositions, cements, methods, and articles

Publications (1)

Publication Number Publication Date
US20130066327A1 true US20130066327A1 (en) 2013-03-14

Family

ID=47830506

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/229,534 Abandoned US20130066327A1 (en) 2011-09-09 2011-09-09 Hydraulic cement compositions with low ph methods, articles and kits
US14/343,105 Active 2033-04-18 US9676665B2 (en) 2011-09-09 2012-09-10 Storage stable premixed hydraulic cement compositions, cements, methods, and articles

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/343,105 Active 2033-04-18 US9676665B2 (en) 2011-09-09 2012-09-10 Storage stable premixed hydraulic cement compositions, cements, methods, and articles

Country Status (1)

Country Link
US (2) US20130066327A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102019211781A1 (en) * 2019-08-06 2021-02-11 Gebr. Brasseler Gmbh & Co. Kg Preparation and ready-mix for use in medical or dental applications, medical or dental product and its use and its manufacture
US12171898B2 (en) 2020-02-19 2024-12-24 Nusmile, Ltd. Bioactive medical ceramic cement

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010055483A2 (en) * 2008-11-12 2010-05-20 Engqvist Haakan Hydraulic cements, methods and products

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2563187B2 (en) 1987-10-13 1996-12-11 旭光学工業株式会社 Method for producing calcium phosphate-based cured product
JP2621622B2 (en) 1990-09-27 1997-06-18 三菱マテリアル株式会社 Hydraulic calcium phosphate cement
US5782971B1 (en) 1991-06-28 1999-09-21 Norian Corp Calcium phosphate cements comprising amorophous calcium phosphate
US5338356A (en) 1991-10-29 1994-08-16 Mitsubishi Materials Corporation Calcium phosphate granular cement and method for producing same
ES2040626B1 (en) 1991-11-22 1994-05-16 Boltong Maria G PROCEDURE FOR THE OBTAINING OF CALCIUM PHOSPHATE CEMENTS AND THEIR USE AS BIOMTERIALS.
US5605713A (en) 1991-11-22 1997-02-25 Boltong; Maria G. Process for the preparation of calcium phosphate cements and its application as bio-materials
US5503164A (en) 1994-01-28 1996-04-02 Osteogenics, Inc. Device and method for repair of craniomaxillofacial bone defects including burr holes
US5569442A (en) 1994-11-04 1996-10-29 Norian Corporation Reactive tricalcium phosphate compositions and uses
US8333996B2 (en) 1995-05-19 2012-12-18 Etex Corporation Calcium phosphate delivery vehicle and adjuvant
US6027742A (en) * 1995-05-19 2000-02-22 Etex Corporation Bioresorbable ceramic composites
US6117456A (en) 1995-05-19 2000-09-12 Etex Corporation Methods and products related to the physical conversion of reactive amorphous calcium phosphate
US5676976A (en) * 1995-05-19 1997-10-14 Etex Corporation Synthesis of reactive amorphous calcium phosphates
US5783217A (en) 1995-11-07 1998-07-21 Etex Corporation Low temperature calcium phosphate apatite and a method of its manufacture
ES2227719T3 (en) 1996-10-16 2005-04-01 Etex Corporation PROCEDURE FOR PREPARATION OF LITTLE CRYSTAL CALCIUM PHOSPHATE AND USING TECHNIQUES.
EP1023032B1 (en) 1997-10-07 2002-01-02 Dr.h.c. Robert Mathys Stiftung Hydraulic surgical cement
DK1023032T3 (en) * 1997-10-07 2002-04-22 Robert Mathys Stiftung Hydraulic surgical cement
FR2772746B1 (en) 1997-12-23 2000-01-28 Commissariat Energie Atomique PROCESS FOR THE MANUFACTURE OF AN APATITIC CERAMIC, PARTICULARLY FOR BIOLOGICAL USE
DE19816858A1 (en) 1998-04-16 1999-10-21 Merck Patent Gmbh Tricalcium phosphate-containing bio-cement pastes with cohesion promoters
US6383519B1 (en) 1999-01-26 2002-05-07 Vita Special Purpose Corporation Inorganic shaped bodies and methods for their production and use
US6642285B1 (en) 1999-02-02 2003-11-04 Robert Mathys Stiftung Implant comprising calcium cement and hydrophobic liquid
WO2000071178A1 (en) 1999-05-19 2000-11-30 Ecole Polytechnique Federale De Lausanne (Epfl) Calcium phosphate bone substitute
US6458162B1 (en) 1999-08-13 2002-10-01 Vita Special Purpose Corporation Composite shaped bodies and methods for their production and use
ES2204198T3 (en) 1999-12-09 2004-04-16 Dr.H.C. Robert Mathys Stiftung HYDRAULIC CEMENT OF BRUSHITA STABILIZED WITH A MAGNESIUM SALT.
ATE243049T1 (en) 1999-12-09 2003-07-15 Biosyntech Canada Inc MINERAL-POLYMER HYBRID COMPOSITION
JP2002000718A (en) 2000-06-26 2002-01-08 Mitsubishi Materials Corp Calcium phosphate cement capable of forming high-strength cured body for bone augmentation treatment of living body
CA2417895C (en) 2000-08-04 2011-09-27 Orthogem Limited Porous synthetic bone graft and method of manufacture thereof
WO2004093734A2 (en) 2002-01-23 2004-11-04 Ada Foundation Premixed self-hardening bone graft pastes
US7294187B2 (en) 2001-01-24 2007-11-13 Ada Foundation Rapid-hardening calcium phosphate cement compositions
US7709029B2 (en) 2001-01-24 2010-05-04 Ada Foundation Calcium-containing restoration materials
CN1162187C (en) * 2001-02-22 2004-08-18 华东理工大学 Inorganic bone adhesive and its application in human hard tissue repair
EP1443981B1 (en) 2001-11-14 2015-05-20 Ecole Polytechnique Fédérale de Lausanne (EPFL) Pasty multiple constituent compositions for injectable calcium phosphate cements
US6840961B2 (en) 2001-12-21 2005-01-11 Etex Corporation Machinable preformed calcium phosphate bone substitute material implants
EP1380313B1 (en) 2002-07-11 2005-05-18 Biomet Deutschland GmbH Method of preparing porous calcium phosphate morsels and granules via Gelatin processing
SE524494C2 (en) 2002-12-31 2004-08-17 Doxa Ab Chemically bonded biomaterial elements with tailored properties
GB0311846D0 (en) 2003-05-23 2003-06-25 Univ Birmingham High strength and injectable apatitic calcium phosphate cements
FR2856672A1 (en) 2003-06-30 2004-12-31 Rhodia Chimie Sa NANOMETRIC CALCIUM PHOSPHATE PLATES.
US7118705B2 (en) 2003-08-05 2006-10-10 Calcitec, Inc. Method for making a molded calcium phosphate article
US7351280B2 (en) 2004-02-10 2008-04-01 New York University Macroporous, resorbable and injectible calcium phosphate-based cements (MCPC) for bone repair, augmentation, regeneration, and osteoporosis treatment
AU2005249365B2 (en) 2004-04-15 2011-04-07 Etex Corporation Delayed-setting calcium phosphate pastes
FR2869544B1 (en) 2004-05-03 2006-07-21 Centre Nat Rech Scient Cnrse COMPOSITION FOR INJECTION CEMENT, USEFUL AS BONE SUBSTITUTE
US7252841B2 (en) 2004-05-20 2007-08-07 Skeletal Kinetics, Llc Rapid setting calcium phosphate cements
US7175858B2 (en) 2004-07-26 2007-02-13 Skeletal Kinetics Llc Calcium phosphate cements and methods for using the same
GB2424223C (en) 2005-03-07 2011-02-02 Massachusetts Inst Technology Biomaterial.
US7459018B2 (en) 2005-04-08 2008-12-02 Howmedica Leibinger Inc. Injectable calcium phosphate cement
AU2005332589B2 (en) 2005-06-09 2011-01-27 Dr. H.C. Robert Mathys Stiftung Shaped article
BRPI0617086B8 (en) 2005-09-09 2021-06-22 Agnovos Healtcare Llc bone graft substitute composite cement and articles originated from it
US9101436B2 (en) 2005-10-21 2015-08-11 Ada Foundation Dental and endodontic filling materials and methods
EP1945233B1 (en) 2005-10-21 2017-03-29 Ada Foundation Dual-phase cement precursor systems for bone repair
EP1948255B1 (en) 2005-11-15 2009-05-27 Dr. h. c. Robert Mathys Foundation Bone repair material
WO2008002682A2 (en) 2006-06-29 2008-01-03 Orthovita, Inc. Bioactive bone graft substitute
CN100425295C (en) 2006-09-19 2008-10-15 天津大学 Premix plaster calcium phosphate bone cement
CA2720269A1 (en) 2007-04-18 2008-10-30 Mcgill University Composition for enhancing bone formation
WO2009077210A1 (en) 2007-10-15 2009-06-25 Universidad Complutense De Madrid Monetite matrices and their application in bone regeneration
WO2009108934A2 (en) * 2008-02-28 2009-09-03 Osteotherapeutics, L.L.C. Injectable calcium phosphate cememts formulated with bioactive agents and methods for making same
WO2010004057A1 (en) 2008-07-08 2010-01-14 Histocell, S.L Three-dimensional matrices of structured porous monetite for tissue engineering and osseous regeneration, and method for the preparation thereof
WO2010094813A1 (en) 2009-02-10 2010-08-26 Azurebio, S. L. Osseous regeneration material from combinations of monetite with other bioactive calcium compounds
US8557038B2 (en) 2009-04-22 2013-10-15 American Dental Association Foundation Dual-phase calcium phosphate cement composition
CA2768876A1 (en) 2009-07-23 2011-01-27 Progentix Orthobiology B.V. Injectable and moldable ceramic materials
EP2512537B1 (en) 2009-12-18 2015-08-26 Howmedica Osteonics Corp. Dual paste direct injectable bone cement precursor systems and methods of making same
KR101901821B1 (en) 2010-03-10 2018-09-27 오에스에스-큐 에이비 Implants and methods for correcting tissue defects
US8591645B2 (en) 2011-09-09 2013-11-26 Ossdsign Ab Hydraulic cements with optimized grain size distribution, methods, articles and kits
TWI439298B (en) 2011-11-28 2014-06-01 Univ Nat Cheng Kung Calcium-based bone cement formula with enhanced non-dispersive ability

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010055483A2 (en) * 2008-11-12 2010-05-20 Engqvist Haakan Hydraulic cements, methods and products

Also Published As

Publication number Publication date
US9676665B2 (en) 2017-06-13
US20140312517A1 (en) 2014-10-23

Similar Documents

Publication Publication Date Title
US9206080B2 (en) Hydraulic cements, methods and products
US20130066324A1 (en) Hydraulic cements, methods and products
US8591645B2 (en) Hydraulic cements with optimized grain size distribution, methods, articles and kits
US20250049986A1 (en) Kits for preparing a reactive graft material and injecting the graft material into a patient
JP5095034B2 (en) System and calcium phosphate composition for producing post-irradiation storage-stable direct-injectable dual-paste bone cement
US20120071884A1 (en) Mixing and dispensing apparatus for bone void filler
HK1249453A1 (en) Multiphasic bone graft substitute material
KR20080096746A (en) Two Phase Cement Precursor System for Bone Regeneration
US20130066327A1 (en) Hydraulic cement compositions with low ph methods, articles and kits
JP6345669B2 (en) Bioabsorbable ceramic composition for forming a three-dimensional scaffold
WO2013035083A2 (en) Storage stable premixed hydraulic cement compositions, cements, methods, and articles
JP2012235856A (en) Biocompatible cement material and its solidification method
HK1230109A1 (en) Multiphasic bone graft substitute material
HK1230109B (en) Multiphasic bone graft substitute material

Legal Events

Date Code Title Description
AS Assignment

Owner name: OSS-Q AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ENGQVIST, HAKAN;ABERG, JONAS;REEL/FRAME:027021/0204

Effective date: 20111003

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION